### 175. calls on the commission to gather more information about the impact of the pandemic on children’s rights and psycho-social development , the empowerment of children regarding their rights , the inclusion of emergency measures concerning children in policy and legislation; ### 175. calls on the commission to gather more information about the impact of the pandemic on children’s rights , such as right to health , in particular with view to long covid in children and psycho-social development , the empowerment of children regarding their rights , the inclusion of emergency measures , but also health consequences of pandemics concerning children in policy and legislation;


### 175. calls on the commission to gather more information about the impact of the pandemic on children’s rights and psycho-social development , the empowerment of children regarding their rights , the inclusion of emergency measures concerning children in policy and legislation; ### 175. calls on the commission to gather more information about the impact of the pandemic on children’s rights an youth’s rights and psycho-social development , the empowerment of children and young people regarding their rights , the inclusion of emergency measures concerning children and youth in policy and legislation;


### 175. calls on the commission to gather more information about the impact of the pandemic on children’s rights and psycho-social development , the empowerment of children regarding their rights , the inclusion of emergency measures concerning children in policy and legislation; ### 175. (does not affect the english version.)


### 60. notes that the pandemic put pressure on global supply chains , including the pharmaceutical sector , resulting in disruptions and unpredictability in the supply of vaccines and other countermeasures; ### 60. notes that the pandemic put pressure on global supply chains , including the pharmaceutical sector , resulting in disruptions and unpredictability in the supply of medicines , medical equipment , vaccines and other countermeasures; highlights the importance of strengthening global supply chains to support the production and free flow of medical countermeasures , including vaccines;


### 60. notes that the pandemic put pressure on global supply chains , including the pharmaceutical sector , resulting in disruptions and unpredictability in the supply of vaccines and other countermeasures; ### 60. notes that the pandemic put pressure on global supply chains , including the pharmaceutical sector , resulting in disruptions and unpredictability in the supply of vaccines , medical supplies and equipment and other countermeasures;


### 62. calls on the commission to consider new processes to promote the repurposing of medicinal products to facilitate broader off-label use of medicines , including less expensive medicines , whenever there is strong scientific evidence of efficacy and safety for patients in order to avoid shortages of medical countermeasures and the effects of disruption in pharmaceutical global supply chains; highlights , in addition , the opportunity for a new framework to support the marketing and use of drugs with new approved indications; ### 62. calls on the commission to consider new processes to promote the repurposing of medicinal products to facilitate broader off-label use of medicines , including less expensive medicines , whenever there is scientific evidence of efficacy and safety for patients; highlights , in addition , the opportunity for a new framework to support the marketing and use of drugs with new approved indications;


### 62. calls on the commission to consider new processes to promote the repurposing of medicinal products to facilitate broader off-label use of medicines , including less expensive medicines , whenever there is strong scientific evidence of efficacy and safety for patients in order to avoid shortages of medical countermeasures and the effects of disruption in pharmaceutical global supply chains; highlights , in addition , the opportunity for a new framework to support the marketing and use of drugs with new approved indications; ### 62. calls on the commission to consider new processes to promote the repurposing of medicinal products to facilitate broader off-label use of medicines , including less expensive medicines , whenever there is strong scientific evidence of efficacy and safety for patients in order to avoid shortages of medical countermeasures and the effects of disruption in pharmaceutical global supply chains; highlights , in addition , the opportunity for a new framework to support the production and use of drugs with new approved indications;


### 63. recalls the critical need for global health and for global supply chains to develop local production and distribution capacities in the eu and in developing countries , notably in terms of pharmaceutical research , development and production and always according to social standards and industry due diligence; calls on the commission to use the industrial , ip and pharmaceutical strategies to bridge the persistent gap in research and medicine production through product-development partnerships and the creation of open centres for research and production; ### 63. recalls the critical need for global health and for global supply chains to develop local production and distribution capacities in the eu and in developing countries , notably in terms of pharmaceutical research , technology , development and production , in line with according to social standards and industry due diligence; calls on the commission to use the industrial , ip and pharmaceutical strategies to bridge the persistent gap in research and medicine production through product-development partnerships and the creation of open centres for research and production;


### 63. recalls the critical need for global health and for global supply chains to develop local production and distribution capacities in the eu and in developing countries , notably in terms of pharmaceutical research , development and production and always according to social standards and industry due diligence; calls on the commission to use the industrial , ip and pharmaceutical strategies to bridge the persistent gap in research and medicine production through product-development partnerships and the creation of open centres for research and production; ### 63. recalls the critical need for global supply chains to develop local production and distribution capacities in the eu and in middle and low income countries , notably in terms of pharmaceutical research , development and production and always according to social standards and industry due diligence; calls on the commission to use the industrial , ip and pharmaceutical strategies to bridge the persistent gap in research and medicine production through product-development partnerships , technology transfer and the creation of open centres for research and production;


### 64. understands that the political and economic consequences of the response to the covid-19 pandemic occurred before health systems were overwhelmed , notably by the collapse of global supply chains; ### deleted


### 64. understands that the political and economic consequences of the response to the covid-19 pandemic occurred before health systems were overwhelmed , notably by the collapse of global supply chains; ### 64. understands that the collapse of global supply chains encouraged the collapse of health systems and had significant political and economic consequences;


### 65. notes that sustainable vaccine development , production and delivery rely on robust and transparent supply chains; calls on the wto to take action to ensure the fluidity of supply chains and vaccine deliveries; ### 65. notes that sustainable vaccine development , production and delivery rely on robust and transparent supply chains; calls on the wto to take action to ensure the fluidity of supply chains and the delivery of vaccines , medicines and medical equipment;


### 65. notes that sustainable vaccine development , production and delivery rely on robust and transparent supply chains; calls on the wto to take action to ensure the fluidity of supply chains and vaccine deliveries; ### 65. notes that globally , sustainable vaccine development , production and delivery rely on robust and transparent supply chains; calls on the wto to take action to ensure the fluidity of supply chains and vaccine deliveries;


### 66. highlights that a framework for compulsory licensing is provided for under the existing agreement on trade-related aspects of intellectual property rights , enabling governments to supply their citizens with generic versions of patented treatments either through domestic production or foreign imports; ### 66. highlights that a framework for compulsory licensing is provided for under the existing agreement on trade-related aspects of intellectual property rights , enabling governments to supply their citizens with generic versions of patented treatments either through domestic production or foreign imports , but underlines that the current framework needs to be improved;


### 66. highlights that a framework for compulsory licensing is provided for under the existing agreement on trade-related aspects of intellectual property rights , enabling governments to supply their citizens with generic versions of patented treatments either through domestic production or foreign imports; ### 66. highlights that a framework for compulsory licensing is provided for under the existing agreement on trade-related aspects of intellectual property rights , enabling governments to supply their citizens with generic drugs;


### 66. highlights that a framework for compulsory licensing is provided for under the existing agreement on trade-related aspects of intellectual property rights , enabling governments to supply their citizens with generic versions of patented treatments either through domestic production or foreign imports; ### 66. highlights that a framework for compulsory licensing is provided for under the existing agreement on trade-related aspects of intellectual property rights but , that its practical use is hindered by regulatory data protection , trade secrets restrictions in import and export of components and finished products produced under a compulsory license;


### 68. believes that the eu needed a common approach for vaccine procurement in order to avoid competition among member states and the undermining of the european project; believes that the exclusivity in the negotiations of vaccines and the early engagement from the member states were successful points in this process; ### 68. believes that the eu needs a common and coordinated approach to face future pandemics and cross border health threats , in particular for the supply of treatments , medicines , medical equipment , medical devices , and vaccines; believes that the eu needed a common approach for vaccine procurement in order to maximise member states bargaining power , to protect and maintain the pillars of the european project and preserve public interests; believes that the exclusivity in the negotiations at the eu level of vaccines was a successful initiative that should be replicated in the future , by for example further broadening joint procurement in the field of health; denounces however , the lack of transparency in the negotiations;


### 68. believes that the eu needed a common approach for vaccine procurement in order to avoid competition among member states and the undermining of the european project; believes that the exclusivity in the negotiations of vaccines and the early engagement from the member states were successful points in this process; ### 68. believes that the eu needed a common approach for the procurement of vaccines , medicines , healthcare supplies and medical equipment in order to avoid competition among member states and the undermining of the european project; believes that the exclusivity in the negotiations of vaccines and the early engagement from the member states were successful points in this process;


### 68. believes that the eu needed a common approach for vaccine procurement in order to avoid competition among member states and the undermining of the european project; believes that the exclusivity in the negotiations of vaccines and the early engagement from the member states were successful points in this process; ### 68. believes that the eu needed a common approach for vaccine procurement in order maximize member states bargaining power , early engagement from the member states were successful points in this process; denounce however the lack of transparency in the negotiations;


### 69. takes the view that joint procurement procedures could provide the eu and its member states with more flexibility according to their needs , whereas negotiations for the advanced purchase agreements were beneficial at a time when the development of vaccines was risky and production lines were prepared without knowing which vaccine would actually succeed or whether the vaccines would actually be approved; ### 69. takes the view that joint procurement procedures could provide the eu and its member states with more flexibility according to their needs;


### 69. takes the view that joint procurement procedures could provide the eu and its member states with more flexibility according to their needs , whereas negotiations for the advanced purchase agreements were beneficial at a time when the development of vaccines was risky and production lines were prepared without knowing which vaccine would actually succeed or whether the vaccines would actually be approved; ### 69. recognize the fundamental role of joint procurement procedures in the medical field in general and for the supply of vaccines and underlines that it could provide the eu and its member states with more flexibility and stability; recalls that negotiations for the advanced purchase agreements were beneficial at a time when the financial sustainability for the development of vaccines was uncertain and production lines were prepared without knowing which vaccine would actually succeed or whether the vaccines would actually be approved;


### 70. stresses the importance of new joint eu voluntary public-procurement contracts by the commission and the member states , especially for , but not limited to , emergency medicines and unmet therapeutic needs , to improve their affordability and access to them at eu level; calls for such practices to be explored in areas such as rare diseases and cancer through clearly outlined milestones , objectives and commitments agreed on by all parties involved; highlights the need to ensure high levels of transparency in these initiatives and to apply lessons learned from the joint procurement of covid-19 products; stresses that joint procurement must not risk having a negative impact on supply flows by increasing the risk of shortages in the eu; ### 70. stresses the importance of new eu joint procurement contracts and asks the commission to further expand their use , particularly in the field of health; recognize their importance especially for , but not limited to , emergency situations and medicines , medical equipment and devices considered critical/essential in case of emergency as well as unmet therapeutic needs , to improve their affordability and access to them at eu level; highlights the need to ensure high levels of transparency in these initiatives and to apply lessons learned from the joint procurement of covid-19 products; stresses that joint procurement must not risk having a negative impact on supply flows by increasing the risk of shortages in the eu; calls for joint procurement initiatives to diversify the number of suppliers which can help ensuring supply security;


### 70. stresses the importance of new joint eu voluntary public-procurement contracts by the commission and the member states , especially for , but not limited to , emergency medicines and unmet therapeutic needs , to improve their affordability and access to them at eu level; calls for such practices to be explored in areas such as rare diseases and cancer through clearly outlined milestones , objectives and commitments agreed on by all parties involved; highlights the need to ensure high levels of transparency in these initiatives and to apply lessons learned from the joint procurement of covid-19 products; stresses that joint procurement must not risk having a negative impact on supply flows by increasing the risk of shortages in the eu; ### 70. stresses the importance of new joint eu voluntary public-procurement contracts by the commission and the member states , especially for , but not limited to , emergency medicines , healthcare supplies and medical equipment and unmet therapeutic needs , to improve their affordability and access to them at eu level; calls for such practices to be explored in areas such as rare diseases and cancer through clearly outlined milestones , objectives and commitments agreed on by all parties involved; highlights the need to ensure maximum levels of transparency in these initiatives and to apply lessons learned from the joint procurement of covid-19 products; stresses that joint procurement must not risk having a negative impact on supply flows by increasing the risk of shortages in the eu;


### 72. highlights the lack of transparency in the joint procurement agreements negotiated with companies , which was justified by respect for the right to confidentiality; stresses that transparency in the work of the eu institutions is of the utmost importance , especially under the conditions of the unprecedented pandemic crisis; ### 72. highlights the lack of transparency in the joint procurement agreements negotiated with companies , which was justified by respect for the right to confidentiality; stresses that transparency in the work of the eu institutions is of the utmost importance , especially under the conditions of the unprecedented pandemic crisis; notes that transparency is crucial not only because vaccines are publicly funded , but also because providing reliable and trustworthy information will help us to tackle the problem of vaccine hesitancy; calls for the european union to adopt a transparency policy for joint procurement and advanced purchase agreements which can be used with future agreements;


### 72. highlights the lack of transparency in the joint procurement agreements negotiated with companies , which was justified by respect for the right to confidentiality; stresses that transparency in the work of the eu institutions is of the utmost importance , especially under the conditions of the unprecedented pandemic crisis; ### 72. regrets the lack of transparency in the joint procurement agreements negotiated by the commission with pharmaceutical companies; stresses that more transparency must be ensured in the future , particularly when public funding is involved and recalls that transparency in the work of the eu institutions is of the utmost importance , especially under the conditions of the unprecedented pandemic crisis; highlights that the european parliament resolution on eu transparency in the development , purchase and distribution of covid-19 vaccines (2021/2678(rsp)) calls on the commission to publish non-redacted versions of the purchase agreements entered into without further delay;


### 72. highlights the lack of transparency in the joint procurement agreements negotiated with companies , which was justified by respect for the right to confidentiality; stresses that transparency in the work of the eu institutions is of the utmost importance , especially under the conditions of the unprecedented pandemic crisis; ### 72. highlights that the lack of transparency in the joint procurement agreements negotiated with companies is not justified by respect for the right to confidentiality; stresses that transparency in the work of the eu institutions is of the utmost importance , even under the conditions of the pandemic crisis;


### 72. highlights the lack of transparency in the joint procurement agreements negotiated with companies , which was justified by respect for the right to confidentiality; stresses that transparency in the work of the eu institutions is of the utmost importance , especially under the conditions of the unprecedented pandemic crisis; ### 72. highlights the lack of transparency in the joint procurement agreements negotiated with companies; stresses that transparency in the work of the eu institutions and officials are of the utmost importance , especially under the conditions of the unprecedented pandemic crisis , good governance and legal compliances;


### 73. observes that the causes of long covid are still scientifically uncertain , as are the specifics of what it includes and its long-term impact; highlights that the eu needs a strategic approach in order to address long covid , focusing on increasing research , training and primary care awareness; ### deleted


### 73. observes that the causes of long covid are still scientifically uncertain , as are the specifics of what it includes and its long-term impact; highlights that the eu needs a strategic approach in order to address long covid , focusing on increasing research , training and primary care awareness; ### 73. observes that the causes of long covid are still scientifically uncertain , as are the specifics of what it includes and its long-term impact; highlights that the eu needs a strategic approach in order to address long covid , focusing on increasing research , training and primary care awareness; stresses the need to focus on researching the causes and treatments of long covid , which is currently an illness for which there are no treatments and which is causing significant financial losses due to time off work and disabilities; highlights the importance of recognising long covid as an occupational disease among healthcare personnel;


### 73. observes that the causes of long covid are still scientifically uncertain , as are the specifics of what it includes and its long-term impact; highlights that the eu needs a strategic approach in order to address long covid , focusing on increasing research , training and primary care awareness; ### 73. observes that both the causes of long covid and the side effects of vaccines , and their long-term impact , are still scientifically uncertain; highlights that the eu needs a strategic approach in order to address long covid and vaccine side effects , focusing on increasing research , training and primary care awareness;


### 73. observes that the causes of long covid are still scientifically uncertain , as are the specifics of what it includes and its long-term impact; highlights that the eu needs a strategic approach in order to address long covid , focusing on increasing research , training and primary care awareness; ### 73. observes that the causes of long covid are still scientifically uncertain , as are the specifics of what it includes and its long-term impact; highlights that the eu needs a strategic approach in order to address long covid , focusing on increasing research , training and primary care awareness , always with a gender-sensitive perspective;


### 74. stresses that the pandemic had consequences for the health of patients with communicable diseases (cds) and non-communicable diseases (ncds) linked to delays and disruptions in diagnostics and treatments , particularly for hiv , hepatitis , cancer and rare diseases , with a massive decrease in screenings for breast and colorectal cancer; ### 74. recalls that immunodepressed and ncds patients were among the most affected during the pandemic , being at greater risk of developing severe simptoms from covid and ultimately paying an enormous price in terms of life loss; stresses that patients with cds and ncds suffered heavy consequences on their health also in terms of delays and disruptions in diagnostics and treatments , particularly for hiv , stds , tuberculosis , hepatitis , cancer , cardiovascular diseases , diabetes and rare diseases , with a massive decrease in screenings for cancer , in particular breast and colorectal cancer; recalls that those vulnerable patients be at great risk in case new pathogens will emerge in the future; calls therefore the commission and member states to urgently develop policies and measures to protect those vulnerable people in case of public health emergencies;


### 74. stresses that the pandemic had consequences for the health of patients with communicable diseases (cds) and non-communicable diseases (ncds) linked to delays and disruptions in diagnostics and treatments , particularly for hiv , hepatitis , cancer and rare diseases , with a massive decrease in screenings for breast and colorectal cancer; ### 74. stresses that the pandemic had consequences for the health of patients with communicable diseases (cds) and non-communicable diseases (ncds) linked to delays and disruptions in diagnostics and treatments , particularly for hiv , hepatitis , tuberculosis , diabetes , cardiovascular and neurological diseases , cancer and rare diseases , with a massive decrease in both access to treatment and screenings for breast , cervical and colorectal cancer;


### 75. observes that the disruptions in cancer screenings , along with other early detection services , have raised serious concerns about long-term consequences , as postponed diagnoses inevitably result in cancer being diagnosed at a later stage , making treatment more complex and costly , and reducing survival probabilities24; ### 75. notes that clinicians across europe saw 1.5 million fewer cancer patients in the first year of the pandemic and an estimated 100 million cancer screening tests were not performed in europe as a result of the pandemic; observes that the disruptions in cancer screenings , along with other early detection services , have raised serious concerns about long-term consequences , as postponed diagnoses inevitably result in cancer being diagnosed at a later stage , making treatment more complex and costly , and reducing survival probabilities24;


### 76. takes note that cd and ncd services were disrupted due to cancellations of elective care , the closure of screening programmes , government or public transport lockdowns which hindered access to the health facilities and lack of staff , and notes that rehabilitation was the most commonly disrupted service; ### deleted


### 76. takes note that cd and ncd services were disrupted due to cancellations of elective care , the closure of screening programmes , government or public transport lockdowns which hindered access to the health facilities and lack of staff , and notes that rehabilitation was the most commonly disrupted service; ### 76. redundant - compare para 74


### 76. takes note that cd and ncd services were disrupted due to cancellations of elective care , the closure of screening programmes , government or public transport lockdowns which hindered access to the health facilities and lack of staff , and notes that rehabilitation was the most commonly disrupted service; ### 76. takes note that cd and ncd services were disrupted due to cancellations of elective care , high testing costs , the closure of screening programmes , government or public transport lockdowns which hindered access to the health facilities and lack of staff and medical infrastructure;


### 77. observes that most countries that have included ncd services in national covid-19 plans have prioritised services for the four major ncds: cardiovascular disease services , cancer services , diabetes services and chronic respiratory disease services; highlights that some countries , like spain , have recognised mental health as an area to prioritise; ### deleted


### 78. highlights the fact that scientifically recognised , integrative medicine approved by public health authorities can bring benefits to patients in relation to the parallel effects of several diseases , such as cancer , and their treatment; stresses the importance of developing a holistic , integrative and patient-centric approach and of encouraging , where appropriate , the complementary use of these therapies under the supervision of healthcare professionals; ### deleted


### 79. recognises that restrictions and lockdowns led to a rise in mental health issues , particularly for youth; underlines , therefore , the importance of introducing such limiting measures as a last resort; calls for support for eu governments’ actions on mental health with a focus on youth and children , while taking into account the limitations of eu competence in this area; ### 79. recognises that restrictions and lockdowns led to a rise in mental health issues , particularly for children and young people; underlines , therefore , the importance of introducing such limiting measures as a last resort; calls for support for eu governments’ actions on mental health with a focus on youth and children; welcomes that , as a response to the conclusions of the conference on the future of europe (cofoe) , the commission committed to put forward a comprehensive mental health strategy by the second quarter of 2023;


### 79. recognises that restrictions and lockdowns led to a rise in mental health issues , particularly for youth; underlines , therefore , the importance of introducing such limiting measures as a last resort; calls for support for eu governments’ actions on mental health with a focus on youth and children , while taking into account the limitations of eu competence in this area; ### 79. recognises that restrictions and lockdowns led to a rise in mental health issues; underlines , therefore , the importance of introducing such limiting measures as a last resort; calls for support for eu governments’ actions on mental health with a focus on youth and children , while taking into account the limitations of eu competence in this area;


### 80. regrets that routine vaccination suffered from setbacks; acknowledges the importance of carrying on and improving these activities to avoid outbreaks of other vaccine-preventable diseases; ### 80. regrets that routine vaccination suffered from setbacks; acknowledges the importance of carrying on and improving vaccination programmes to avoid outbreaks of other diseases that could be prevented with health promotion and disease prevention programmes; points out , at the same time , that covid19 is not over and that the eu and its member states need to remain alert and keep ensuring access to covid19 vaccines; notes that one way of achieving this is to use routine vaccination against covid19 , particularly in vulnerable groups;


### 80. regrets that routine vaccination suffered from setbacks; acknowledges the importance of carrying on and improving these activities to avoid outbreaks of other vaccine-preventable diseases; ### 80. highlights that the pandemic has fueled a severe backsliding in routine immunization and regrets that routine vaccination has suffered from setbacks; acknowledges the importance of carrying on and improving these activities to avoid outbreaks of other vaccine-preventable diseases and to ensure equal access to essential and life-savings vaccines at global level;


### 80. regrets that routine vaccination suffered from setbacks; acknowledges the importance of carrying on and improving these activities to avoid outbreaks of other vaccine-preventable diseases; ### 80. regrets that routine vaccination suffered from setbacks , amongst which , disinformation; acknowledges the importance of carrying on and improving these activities to avoid outbreaks of other vaccine-preventable diseases;


### 80. regrets that routine vaccination suffered from setbacks; acknowledges the importance of carrying on and improving these activities to avoid outbreaks of other vaccine-preventable diseases; ### 80. acknowledges the importance of carrying on and improving national vaccination programmes already under way in member states , to avoid outbreaks of other vaccine-preventable diseases;


### 81. insists that covid-19 and other recent epidemics and pandemics have made it unmistakably clear that human , animal , plant and environmental health cannot be dealt with separately , but need to be addressed in a ‘one health’ approach; highlights that their interdependencies need to be better acknowledged and require intersectional work using a multi-sectoral , transdisciplinary and integrated approach; recalls that 75% of human infectious diseases are zoonotic and that the threat of increasing antimicrobial resistance is one of the leading causes of death worldwide; ### 81. insists that covid-19 and other recent epidemics and pandemics have made it unmistakably clear that human , animal , plant and environmental health cannot be dealt with separately , but need to be addressed in a ‘one health’ approach; highlights that their interdependencies need to be better acknowledged and require intersectional work using a multi-sectoral , transdisciplinary and integrated approach; recalls that 75% of human infectious diseases are zoonotic and that the threat of increasing antimicrobial resistance is one of the leading causes of death worldwide; notes that emerging zoonotic infectious diseases are becoming increasingly common and that , in order to tackle new threats of diseases such as covid19 , the european union needs to emphasise ‘one health’ in its public health policies;


### 81. insists that covid-19 and other recent epidemics and pandemics have made it unmistakably clear that human , animal , plant and environmental health cannot be dealt with separately , but need to be addressed in a ‘one health’ approach; highlights that their interdependencies need to be better acknowledged and require intersectional work using a multi-sectoral , transdisciplinary and integrated approach; recalls that 75% of human infectious diseases are zoonotic and that the threat of increasing antimicrobial resistance is one of the leading causes of death worldwide; ### 81. insists that covid-19 and other recent epidemics and pandemics have made it unmistakably clear that human , animal , plant and environmental health cannot be dealt with separately , but need to be addressed in a ‘one health’ approach; highlights that their interdependencies need to be better acknowledged and require intersectional work using a multi-sectoral , transdisciplinary and integrated approach; recalls that 75% of human infectious diseases are zoonotic and that the threat of increasing antimicrobial resistance is one of the leading causes of death worldwide which can be reduced by introducing health education in all educational institutions in the member states;


### 81. insists that covid-19 and other recent epidemics and pandemics have made it unmistakably clear that human , animal , plant and environmental health cannot be dealt with separately , but need to be addressed in a ‘one health’ approach; highlights that their interdependencies need to be better acknowledged and require intersectional work using a multi-sectoral , transdisciplinary and integrated approach; recalls that 75 % of human infectious diseases are zoonotic and that the threat of increasing antimicrobial resistance is one of the leading causes of death worldwide; ### 81. stresses that covid-19 and other recent epidemics and pandemics have made it unmistakably clear that human , animal , plant and environmental health are inextricably interlinked and need to be addressed in a coherent and holistic manner , in full respect of the ‘one health’ approach as defined by the who and underlines that transformative changes are urgently needed across society; highlights the need to further expand knowledge in this field and promote public research in order to define better their interdependencies using a multi-sectoral , transdisciplinary and integrated approach;


### 82. underline that mainstreaming one health means better able to prevent , predict , prepare for , detect and respond to global health threats at both global and eu level; recommends that the one health approach be designed and implemented through public policies , legislation and research with the engagement of multiple sectors; ### 82. underline that the one health approach should be a guiding principle in all public policies initiatives and measures , to be mainstreamed horizontally in order to better prevent , predict , prepare for , detect and respond to global health threats at global , eu level and national level; recommends for the one health approach to be designed and implemented through public policies , legislation and research with the engagement of multiple sectors; highlights the need to strengthen the coordination of the health sector with other sectors;


### 82. underline that mainstreaming one health means better able to prevent , predict , prepare for , detect and respond to global health threats at both global and eu level; recommends that the one health approach be designed and implemented through public policies , legislation and research with the engagement of multiple sectors; ### 82. underline that mainstreaming one health means better able to prevent , educate , predict , prepare for , detect and respond to global health threats at both global and eu level; recommends that the one health approach be designed and implemented through public policies , legislation , measures to support health education , the development of good practice guides and research , targeting multiple sectors;


### 83. encourages the eu and member states to implement the european health union package , developing a permanent agenda for health and looking at healthcare as an investment; calls for basic health services to be strengthened , as a way of improving the general state of health of the population; ### 83. encourages the eu and member states to implement the european health union package , developing a permanent agenda for health and looking at healthcare as an investment; calls for healthcare services to be strengthened and made available to all , without discrinations , as a way of improving the general state of health of the population;


### 83. encourages the eu and member states to implement the european health union package , developing a permanent agenda for health and looking at healthcare as an investment; calls for basic health services to be strengthened , as a way of improving the general state of health of the population; ### 83. encourages the eu and member states to implement the european health union package , developing a permanent agenda for health and looking at health education and healthcare as an investment; calls for basic health services to be strengthened , as a way of improving the general state of health of the population;


### 84. highlights the need to ensure the performance of epidemiological surveillance at eu level and the availability and interoperability of information systems , new tools and research to strengthen interdisciplinary research and human and social sciences as regards the impact of pandemics and non-pharmaceutical measures; ### 84. stresses the need to further enhance capabilities to perform epidemiological surveillance at eu level throught the implementation of mandatory plans for surveillance , monitoring and preparedness both at eu and national level; underlines to this end importance of information sharing and their availability among member states and european authorities , the interoperability of information systems , new tools and research to strengthen interdisciplinary research and human and social sciences as regards the impact of pandemics and non-pharmaceutical measures;


### 84. highlights the need to ensure the performance of epidemiological surveillance at eu level and the availability and interoperability of information systems , new tools and research to strengthen interdisciplinary research and human and social sciences as regards the impact of pandemics and non-pharmaceutical measures; ### 84. highlights the need to ensure the performance of epidemiological surveillance at eu level and the availability and interoperability of information systems , new tools and research to strengthen interdisciplinary research and human and social sciences as regards the impact of pandemics and non-pharmaceutical measures; calls for the activities on data collection and surveillance of covid-19 to be maintained , in order mitigate any potential future public health threat from the endemic spread of the disease;


### 85. calls for eu guidance to improved when healthcare services are temporarily stopped , decreased or diverted , identifying priority patients who should continue to be diagnosed and to receive treatment; ### deleted


### 85. calls for eu guidance to improved when healthcare services are temporarily stopped , decreased or diverted , identifying priority patients who should continue to be diagnosed and to receive treatment; ### 85. calls for eu guidance to improved when healthcare services are temporarily stopped , decreased or diverted , identifying priority patients who should continue to be diagnosed and to receive treatment , and for an improvement in the capacity to provide qualified personnel , equipment and healthcare supplies , and medical infrastructure to address specific treatment needs for these patients;


### 86. urges the further digitalisation of administrative services and , wherever appropriate and feasible , the use of online healthcare services; ### deleted


### 86. urges the further digitalisation of administrative services and , wherever appropriate and feasible , the use of online healthcare services; ### 86. urges the further digitalisation of administrative services and , wherever appropriate and feasible , the use of online healthcare services , whilst ensuring the adequate level of digital skills for the workers and professionals personnel as well as for the caregivers involved;


### 176. calls , in this regard , for the eu and member states to boost funding for eu research on children in general and children’s data; ### 176. calls , in this regard , for the eu and member states to boost funding for eu research on children in general and children’s data; is concerned that the mildness of symptoms has contributed to less diagnostic testing and therefore the detection of fewer cases of covid-19 in these age groups; calls for a registry of children and adolescents with symptoms of persistent covid-19 , along with appropriate follow-up to minimise the effects of the disease;


### 176. calls , in this regard , for the eu and member states to boost funding for eu research on children in general and children’s data; ### 176. calls , in this regard , for the eu and member states to boost funding for eu research on children in general and children’s data as well as the provision of access to health education;


### 176. calls , in this regard , for the eu and member states to boost funding for eu research on children in general and children’s data; ### 176. calls , in this regard , for the eu and member states to boost funding for eu research on children and youth in general and their data;


### 177. recommends that , in future pandemics , schools and other education facilities should remain open , and education policy should be part of an emergency response strategy; ### 177. recommends that , in future pandemics , schools and other education facilities should remain open when possible , flexible individual solutions should be offered , digitalisation of schools should be supported and constantly developed and a comprehensive education policy taking all aspects of impacts on children and their families into account should be part of an emergency response strategy;


### 177. recommends that , in future pandemics , schools and other education facilities should remain open , and education policy should be part of an emergency response strategy; ### 177. calls for a clear action plan for schools; recommends that , in future pandemics , schools and other education facilities should remain open if the epidemiological situation allows it and always considering the protection of people's life and public health concern as the main priority; asks for education policy to be part of the emergency response strategy;


### 177. recommends that , in future pandemics , schools and other education facilities should remain open , and education policy should be part of an emergency response strategy; ### 177. recommends that , in future pandemics , all solutions discussed should take account of concrete medical data , and education policy should be part of an emergency response strategy;


### 178. recommends that unicef’s guidance on child rights impact assessment should be applied to policymaking , legislation and emergency measures to avoid negative repercussions on children; ### 178. recommends that unicef’s guidance on child rights impact assessment should be applied to policymaking , legislation and emergency measures to avoid negative repercussions on children; recognises the increased stress and/or anxiety resulting from the pandemic in young people and children , and calls for mental health services and support to be made available to all;


### 178. recommends that unicef’s guidance on child rights impact assessment should be applied to policymaking , legislation and emergency measures to avoid negative repercussions on children; ### 178. recommends that unicef’s guidance on child rights impact assessment should be taken into account in policymaking , legislation and emergency measures to avoid negative repercussions on children;


### 179. calls on the commission to carry out a ‘youth and elderly proof check’ for all the eu’s legislative proposals; ### 179. calls on the commission to carry out and present to the european parliament a report on a ‘youth and elderly proof check’ for all the eu’s legislative proposals , including those relating to the policy decision on the introduction of the digital green certificate;


### 179. calls on the commission to carry out a ‘youth and elderly proof check’ for all the eu’s legislative proposals; ### 179. calls on the commission to carry out a ‘children , youth and elderly proof check’ for all the eu’s legislative proposals; ;


### 179. calls on the commission to carry out a ‘youth and elderly proof check’ for all the eu’s legislative proposals; ### 179. (does not affect the english version.)


### 180. welcomes the green paper on ageing and calls for the eu and member states to take urgent action to address the health and care needs of an ageing european population including addressing ncds; ### 180. welcomes the green paper on ageing and calls for the eu and member states to take urgent action to address the health and care needs of an ageing european population including addressing ncds through the promotion of active and healthy ageing in line with the who’s decade for healthy ageing;


### 180. welcomes the green paper on ageing and calls for the eu and member states to take urgent action to address the health and care needs of an ageing european population including addressing ncds; ### 180. welcomes the green paper on ageing as the first step for an overall eu strategy to address the ageing of the population in europe; stresses the need for eu and member states to take urgent and to prepare a eu strategy to address the health and care needs of an ageing european population including addressing ncds;


### 180. welcomes the green paper on ageing and calls for the eu and member states to take urgent action to address the health and care needs of an ageing european population including addressing ncds; ### 180. calls for the eu and member states to take urgent action to address the health and care needs of an ageing european population without neglecting children and young people in less economically developed eastern european union countries , including addressing ncds;


### 181. notes that as the potential for longevity increases , so does the importance of health-related behaviours at all ages (including middle and older ages); calls therefore for healthy longevity research and measures to better prevent ncds , to reduce the impact of cds , and make ageing an opportunity rather than an adversity; ### 181. notes that as the potential for longevity increases , so does the importance of health-related behaviours at all ages (including middle and older ages); calls therefore for healthy longevity research and uniform measures to better prevent ncds , to reduce the impact of cds and establish european health quality standards so that population ageing is managed appropriately;


### 181. notes that as the potential for longevity increases , so does the importance of health-related behaviours at all ages (including middle and older ages); calls therefore for healthy longevity research and measures to better prevent ncds , to reduce the impact of cds , and make ageing an opportunity rather than an adversity; ### 181. notes that as the potential for longevity increases , so does the importance of health-related behaviours at all ages (including middle and older ages); calls therefore for healthy longevity research and measures to better prevent ncds , to reduce the impact of cds , to account for and respond to multimorbidity and polypharmacy , and make ageing an opportunity rather than an adversity;


### 181. notes that as the potential for longevity increases , so does the importance of health-related behaviours at all ages (including middle and older ages); calls therefore for healthy longevity research and measures to better prevent ncds , to reduce the impact of cds , and make ageing an opportunity rather than an adversity; ### 181. notes that as the potential for longevity increases , so does the importance of promoting healthy environments and lifestyles at all ages (including adults and the elderly); calls therefore for research into ageing; from an equity and life-course perspective;


### 182. calls for the eu and member states to invest and develop online tools and digitally empower older people , support online healthcare services and institutions financially and to develop support measures for caregivers; ### 182. calls for the eu and member states to address “digital poverty” , invest and develop online tools and digitally empower older people , people with a disability , young people and vulnerable people , support online healthcare services and institutions financially and to develop support measures for caregivers;


### 182. calls for the eu and member states to invest and develop online tools and digitally empower older people , support online healthcare services and institutions financially and to develop support measures for caregivers; ### 182. calls for the eu and member states to invest and develop online tools and digitally empower older people , support online healthcare services and institutions financially and to develop support measures for caregivers , ensuring access to the internet to all as well as the adequate digital skills ;


### 182. calls for the eu and member states to invest and develop online tools and digitally empower older people , support online healthcare services and institutions financially and to develop support measures for caregivers; ### 182. (does not affect the english version.)


### 183. is of the opinion that there is a need to further develop innovative solutions that emerged during the pandemic , such as new modes of working , digitalisation and access for all; calls for the re- and upskilling of older workers; ### 183. is of the opinion that there is a need to further develop innovative solutions that emerged during the pandemic , such as online tools and digitally empower older people , support online healthcare services and institutions financially and to develop support measures for caregivers; such as new modes of working , digitalisation and access for all; calls for the re- and upskilling of older workers;


### 183. is of the opinion that there is a need to further develop innovative solutions that emerged during the pandemic , such as new modes of working , digitalisation and access for all; calls for the re- and upskilling of older workers; ### 183. calls for the innovative solutions that proved to be effective during the pandemic to be developed further , such as new modes of working , digitalisation and access for all; calls for the re- and upskilling of older workers , especially those in eastern european union countries;


### 183. is of the opinion that there is a need to further develop innovative solutions that emerged during the pandemic , such as new modes of working , digitalisation and access for all; calls for the re- and upskilling of older workers; ### 183. (does not affect the english version.)


### 184. recommends that the eu and member states invest in a health and care plan for the growing elderly population; ### 184. recommends that the eu and member states invest in a health and care plan from a life-course perspective for the growing elderly population promoting the goal of healthy ageing from before birth;


### 184. recommends that the eu and member states invest in a health and care plan for the growing elderly population; ### 184. calls on the eu and member states to develop and finance a uniform care and health plan for elderly people from which all european union citizens will benefit;


### 185. recommends that member states should carefully evaluate the risk-benefit of the restrictions on physical activity before implementing them; considers that during a health crisis , governments should provide guidance and encourage better diets , physical activity for people with special focus on the vulnerable and disadvantaged groups , in order to increase the resilience of populations in member states in the event of a future pandemic; ### 185. asks governments , during any health crisis , to provide guidance , inform and provide access to better diets and physical activity , with special focus on vulnerable and disadvantaged groups in eastern european union countries;


### 186. calls for the eu and member states to invest in a disability-inclusive process of preparedness , to prevent the devastating impacts of future crises; ### 186. calls for the eu and member states to invest in a disability-inclusive process of preparedness for health education , to prevent the devastating impacts of future crises;


### 187. notes that in spite of massive growth in the trade of medical products , there have been considerable inefficiencies in access to personal protection equipment; ### 187. notes that in spite of massive growth in the trade of medical products , there have been considerable inefficiencies in access to personal protection equipment; treatments , vaccines and diagnostics , deplores export controls on health goods placed in the early stages of the pandemic in eu and globally;


### 187. notes that in spite of massive growth in the trade of medical products , there have been considerable inefficiencies in access to personal protection equipment; ### 187. notes that in spite of massive growth in the trade of medical products , there have been considerable inefficiencies in access to personal protection equipment , medicines and healthcare supplies and equipment;


### 188. notes that it is the governments’ responsibility to facilitate the distribution of medical products and that the wto’s role in this regard is to implement international trade facilitation , to promote international regulatory cooperation in order to boost goods imports and to reduce export bans or restrictions which are detrimental for access to vaccines; ### 188. notes that it is the governments’ responsibility to facilitate the distribution of medical products and that the wto’s role in this regard is to facilitate international trade through international cooperation;


### 188. notes that it is the governments’ responsibility to facilitate the distribution of medical products and that the wto’s role in this regard is to implement international trade facilitation , to promote international regulatory cooperation in order to boost goods imports and to reduce export bans or restrictions which are detrimental for access to vaccines; ### 188. notes that it is the governments’ responsibility to facilitate the distribution of medical products and that the wto’s role in this regard is to implement international trade facilitation , to promote international regulatory cooperation in order to boost goods imports and to reduce export bans or restrictions which are detrimental for access to vaccines , medicines and healthcare supplies and equipment;


### 188. notes that it is the governments’ responsibility to facilitate the distribution of medical products and that the wto’s role in this regard is to implement international trade facilitation , to promote international regulatory cooperation in order to boost goods imports and to reduce export bans or restrictions which are detrimental for access to vaccines; ### 188. notes that it is the member states’ responsibility to facilitate the distribution of medical products and that the wto’s role in this regard is to implement international trade facilitation , to promote international regulatory cooperation in order to boost goods imports and to reduce export bans or restrictions which are detrimental for access to vaccines;


### 189. notes the eu’s dependency on external sources of personal protection equipment and questions the role of the wto in terms of supply chains in this regard; ### 189. notes the eu’s dependency on external sources of personal protection equipment , medicines and healthcare supplies and equipment and questions the role of the wto in terms of supply chains in this regard;


### 189. notes the eu’s dependency on external sources of personal protection equipment and questions the role of the wto in terms of supply chains in this regard; ### 189. notes the eu’s dependency on external sources of personal protection equipment;


### 190. highlights that tariff and non-tariff barriers have limited access to vaccines , and considers that the wto should take action to ensure the free flow of supply chains and vaccine deliveries , notably as regards export restrictions; ### 190. highlights that tariff and non-tariff barriers have limited access to medicines , healthcare supplies and equipment and vaccines , and considers that the wto should take action to ensure the free flow of supply chains and deliveries of medicines and healthcare supplies and equipment , vaccines , notably as regards export restrictions;


### 190. highlights that tariff and non-tariff barriers have limited access to vaccines , and considers that the wto should take action to ensure the free flow of supply chains and vaccine deliveries , notably as regards export restrictions; ### 190. highlights that multiple factors have limited access to vaccines , and considers that the wto should take action to ensure lifting of intellectual property barriers , the free flow of supply chains and vaccine deliveries , notably as regards export restrictions;


### 191. calls for the eu to focus on open strategic autonomy supporting supply chain diversification and resilience , with an open , rules-based multilateral trading system at its core to ensure the global availability of medical products and complemented by a ‘strategic supply chain diversification fund’ to actively support our companies; encourages all countries to join the wto’s agreement on trade in pharmaceutical products and urge for its scope to be extended to all pharmaceutical and medicinal products; ### deleted


### 191. calls for the eu to focus on open strategic autonomy supporting supply chain diversification and resilience , with an open , rules-based multilateral trading system at its core to ensure the global availability of medical products and complemented by a ‘strategic supply chain diversification fund’ to actively support our companies; encourages all countries to join the wto’s agreement on trade in pharmaceutical products and urge for its scope to be extended to all pharmaceutical and medicinal products; ### 191. calls for the eu to focus on open strategic autonomy supporting supply chain diversification and resilience , with an open , rules-based multilateral trading system at its core to ensure the global availability of medical products , medicines and healthcare supplies and equipment and complemented by a ‘strategic supply chain diversification fund’ to actively support our companies so that all existing development and research capacities in the member states , such as the “cantacuzino” national institute for military medical research and development in romania , can be used in future; encourages all countries to join the wto’s agreement on trade in pharmaceutical products and urge for its scope to be extended to all pharmaceutical and medicinal products;


### 191. calls for the eu to focus on open strategic autonomy supporting supply chain diversification and resilience , with an open , rules-based multilateral trading system at its core to ensure the global availability of medical products and complemented by a ‘strategic supply chain diversification fund’ to actively support our companies; encourages all countries to join the wto’s agreement on trade in pharmaceutical products and urge for its scope to be extended to all pharmaceutical and medicinal products; ### 191. calls for the eu to focus on open strategic autonomy supporting supply chain diversification and resilience , with an open , rules-based multilateral trading system at its core to ensure the global availability of medical products and complemented by a ‘strategic supply chain diversification fund’ to actively support our companies; encourages all countries to join the wto’s agreement on trade in pharmaceutical products and urge for its scope to be extended to all pharmaceutical and medicinal products; advocates support for european pharmaceutical smes that would contribute to the development of a diverse portfolio of vaccines and thus to the eu’s strategic autonomy in the health sector;


### 191. calls for the eu to focus on open strategic autonomy supporting supply chain diversification and resilience , with an open , rules-based multilateral trading system at its core to ensure the global availability of medical products and complemented by a ‘strategic supply chain diversification fund’ to actively support our companies; encourages all countries to join the wto’s agreement on trade in pharmaceutical products and urge for its scope to be extended to all pharmaceutical and medicinal products; ### 191. calls for the eu to focus on open strategic autonomy and supporting global diversification and resilience of supply chain , with an open , rules-based multilateral trading system at its core to ensure the global availability of medical products and complemented by a ‘strategic supply chain diversification fund’ to actively support our companies; encourages all countries to join the wto’s agreement on trade in pharmaceutical products and urge for its scope to be extended to all pharmaceutical and medicinal products;


### 192. notes that patent protection is a key incentive for companies to invest in innovation and to produce new medicines; notes , at the same time , that the exclusionary effect of patents may lead to limited market supply and reduced access to medicines and pharmaceutical products; stresses that a balance should be struck between encouraging innovation through the exclusionary effect of patents and ensuring access to medicines and protecting public health; ### 192. notes that patent protection is an incentive for companies to invest in innovation and to produce new medicines that should be placed at the service of citizens and to promote public interest; notes , at the same time , that in time of crisis and to protect public health and people's life , public authorities should be able to interve on this system and use all means needed to grant access to treatment and care to everyone; recalls that the exclusionary effect of patents has led and may lead to limited market supply and reduced access to medicines and pharmaceutical products; stresses that a balance should be struck between encouraging innovation and ensuring access to medicines and protecting public health; recalls that public funding has been decisive in the development of vaccines and treatment for covid; stresses the need to ensure that public funding for biomedical r&d includes conditions for the availability , accessibility and affordability of end-products , other than full transparency on r&d actual cost and the contracts and procurement processes;


### 192. notes that patent protection is a key incentive for companies to invest in innovation and to produce new medicines; notes , at the same time , that the exclusionary effect of patents may lead to limited market supply and reduced access to medicines and pharmaceutical products; stresses that a balance should be struck between encouraging innovation through the exclusionary effect of patents and ensuring access to medicines and protecting public health; ### 192. stresses that a balance should be struck between encouraging innovation through the exclusionary effect of patents and ensuring access to medicines and protecting public health;


### 192. notes that patent protection is a key incentive for companies to invest in innovation and to produce new medicines; notes , at the same time , that the exclusionary effect of patents may lead to limited market supply and reduced access to medicines and pharmaceutical products; stresses that a balance should be struck between encouraging innovation through the exclusionary effect of patents and ensuring access to medicines and protecting public health; ### 192. notes the importance of public and private investments in innovation and to produce medical tools; notes , at the same time , that the exclusionary effect of patents and other forms of ip protection may lead to limited market supply , exhorbitant prices and reduced access to medicines and pharmaceutical products; stresses the need to actively encourage access to innovation and protecting public health;


### 193. stresses that wto free trade agreements should not focus exclusively on enforcing ip standards in third countries , but should take into account the impact on generic and biosimilar medicines both in the eu and in third countries , as well as ensure coordination of regulatory standards; ### 193. stresses that eu trade agreements should not focus on enforcing ip standards on third countries , but should take into account the impact on generic and biosimilar medicines both in the eu and in third countries;


### 194. welcomes the fact that the eu and who have been and remain in close cooperation on every aspect of responses to the pandemic; calls for stronger , more coordinated , international cooperation taking a long-term view and with a stronger who at the centre; ### 194. notes that the eu and who have been and remain in close cooperation on every aspect of responses to the pandemic; calls for stronger international cooperation with a reformed who at the centre;


### 194. welcomes the fact that the eu and who have been and remain in close cooperation on every aspect of responses to the pandemic; calls for stronger , more coordinated , international cooperation taking a long-term view and with a stronger who at the centre; ### 194. welcomes the cooperation between the eu and who in the responses to the pandemic; underlines the need to further reinforce this cooperation with a stronger , more coordinated , international cooperation taking a long-term view and with a stronger un system at the centre;


### 195. emphasises that who accompanied countries from the beginning to the end of their vaccine strategy , until the very last steps of delivery; considers , however , that there were delays and uncertainties in supply , especially in 2021 , and that the situation improved only once global supply was largely meeting global demand; ### 195. emphasises that there were delays and uncertainties in the supply of medicines and healthcare supplies and equipment , especially in 2021;


### 195. emphasises that who accompanied countries from the beginning to the end of their vaccine strategy , until the very last steps of delivery; considers , however , that there were delays and uncertainties in supply , especially in 2021 , and that the situation improved only once global supply was largely meeting global demand; ### 195. emphasises that who and unicef accompanied countries from the beginning to the end of their vaccine strategy , until the very last steps of delivery; considers , however , that there were delays and uncertainties in supply , especially in 2021 , and that the situation improved only once global supply was largely meeting global demand;


### 196. underlines the need to place safeguards on re-exports in order to prevent illicit trade and avoid boosting existing markets; recognises that the destination must be an eligible country but that in the event of a humanitarian emergency , an initially non-eligible country may be the destination; ### 196. calls for the creation of new safeguards on re-exports in order to prevent illicit trade and avoid boosting existing markets; recognises that the destination must be an eligible country but that in the event of a humanitarian emergency , an initially non-eligible country may be the destination;


### 197. considers that a multilateral and globally coordinated response is crucial to building up global resilience against future health crises , and that global mechanisms need to be given more importance; notes in this regard that such mechanisms need to work on their own improvement; ### 197. considers that global health crisis response mechanisms need to work on their own improvement;


### 197. considers that a multilateral and globally coordinated response is crucial to building up global resilience against future health crises , and that global mechanisms need to be given more importance; notes in this regard that such mechanisms need to work on their own improvement; ### 197. considers that a multilateral and globally coordinated response is crucial to building up global resilience against future health crises , and that multilateral organisations , particularly of the un system , must be reinforced in order to fulfil their mandate;


### 198. underlines that one health should be among the most prominent subjects of discussion within the who , particularly as regards to the animal-human interface; notes that , although the who one health panel already has given recommendations , there is still a need to find ways to implement them; ### 198. underlines that one health is the right solution to prevent and manage health crises;


### 198. underlines that one health should be among the most prominent subjects of discussion within the who , particularly as regards to the animal-human interface; notes that , although the who one health panel already has given recommendations , there is still a need to find ways to implement them; ### 198. underlines that the one health approach is fundamental in order to address global public health challenges and it must be the guiding principle and reference for public policies as regards to the animal-human interface and the approach against anti-microbial resistence; notes that , although the who one health panel already has given recommendations , these needs to be better reflected into concrete policies , measures and regulations at eu , national and regional level;


### 199. demands that the role of parliaments be taken into account in international discussions in order to increase the legitimacy of those discussions; ### 199. demands that the role of parliaments be taken into account in international discussions in order to increase the legitimacy of those discussions; in order to strengthen this legitimacy , advocates information exchange at international level , which should cover from preparedness (laboratory capacities , testing , early detection , epidemiological surveillance , etc.) to response (decision-making based on scientific evidence and available data , multi-sectoral coordination processes , communication to the public and health professionals , etc.);


### 199. demands that the role of parliaments be taken into account in international discussions in order to increase the legitimacy of those discussions; ### 199. demands that the role of national parliaments and the european parliament be taken into account in international decisions concerning health , in order to increase the legitimacy of those decisions;


### 200. highlights the fact that covid-19 vaccines global access (covax) was key to delivering vaccines to low and middle-income countries given that their facilities and capacities were built on existing ones; notes that most of low and middle-income countries’ doses came from covax; ### 200. highlights the fact that covid-19 vaccines global access (covax) was key to delivering vaccines to low and middle-income countries but did not live up to expectations , accumulating delays and failing to meet lmic needs; notes that most of low and middle-income countries’ doses came from covax;


### 200. highlights the fact that covid-19 vaccines global access (covax) was key to delivering vaccines to low and middle-income countries given that their facilities and capacities were built on existing ones; notes that most of low and middle-income countries’ doses came from covax; ### 200. highlights the fact that covid-19 vaccines global access (covax) was created with the aim of delivering vaccines to low and middle-income countries , but it did not live up to expectations , accumulatin delays and failing to meet lmic needs;


### 200. highlights the fact that covid-19 vaccines global access (covax) was key to delivering vaccines to low and middle-income countries given that their facilities and capacities were built on existing ones; notes that most of low and middle-income countries’ doses came from covax; ### 200. notes the importance of covid-19 vaccines global access (covax) for delivering vaccines to low and middle-income countries given that their facilities and capacities were built on existing ones; notes that most of low and middle-income countries’ doses came from covax;


### 201. recognises that there is considerable effort at the global scale to increase production capacity; welcomes the fact that the eu became a model in that matter and a large investor both in terms of push (before development) and pull (advance purchase agreements) investments , which made it possible to secure enough vaccines; ### 201. recognises that there is considerable effort at the global scale to increase production capacity; welcomes the fact that the eu became a model in that matter and a large investor both in terms of push (before development) and pull (advance purchase agreements) investments , which made it possible to secure enough vaccines but regrets the fact this was not the case with medicines and healthcare supplies and equipment and the lack of transparency over advance purchase agreements and contracts relating to vaccines;


### 201. recognises that there is considerable effort at the global scale to increase production capacity; welcomes the fact that the eu became a model in that matter and a large investor both in terms of push (before development) and pull (advance purchase agreements) investments , which made it possible to secure enough vaccines; ### 201. recognises that there is considerable effort at the global scale to increase production capacity , supported with a large use of public funds; welcomes the fact that the eu became a model in that matter and a large investor both in terms of push (before development) and pull (advance purchase agreements) investments , which made it possible to secure enough vaccines; recalls that public investments must bring public return in terms of affordability , availability and accessibility of the end products;


### 202. underlines that public-private cooperation during a pandemic emergency is structurally different from cooperation under ‘normal’ circumstances , where the public side provides long-term investment , additional grants or loans and the private side delivers the product; emphasises that in a pandemic situation , where much more risk is involved , public funding plays an even bigger role in the development cycle of the product (vaccine) , in conjunction with advance purchase agreements before regulatory approval; notes that this can work only if global frameworks are well crafted and if there is close coordination between all the actors involved; ### 202. underlines that public-private cooperation during a pandemic emergency has been decisive to address the challenge and deliver vaccines; recalls that a large amount of public funding played a key role in the development cycle of the product (vaccine) , in conjunction with advance purchase agreements before regulatory approval;


### 202. underlines that public-private cooperation during a pandemic emergency is structurally different from cooperation under ‘normal’ circumstances , where the public side provides long-term investment , additional grants or loans and the private side delivers the product; emphasises that in a pandemic situation , where much more risk is involved , public funding plays an even bigger role in the development cycle of the product (vaccine) , in conjunction with advance purchase agreements before regulatory approval; notes that this can work only if global frameworks are well crafted and if there is close coordination between all the actors involved; ### 202. underlines that public-private cooperation during a pandemic emergency is not structurally different from cooperation under ‘normal’ circumstances but warns that in a pandemic situation , public funding plays an even bigger role in the development cycle of the product , in conjunction with advance purchase agreements before regulatory approval; notes that this can work only if global frameworks for increased transparency in medical product purchase , production and distribution chains , are well crafted and if there is close coordination between all the actors involved;


### 203. considers that team europe has proved to be central in terms of solidarity and underlines the eu’s leadership in the global response to the pandemic; ### deleted


### 203. considers that team europe has proved to be central in terms of solidarity and underlines the eu’s leadership in the global response to the pandemic; ### 203. considers that the european response has proved to be important in terms of solidarity and underlines the eu’s leadership in the global response to the pandemic;


### 204. notes that team europe has played a key role in supporting r&d efforts in africa to address the provision of critical resources and technical support to help african countries respond effectively to the pandemic and build resilience for the future; ### deleted


### 204. notes that team europe has played a key role in supporting r&d efforts in africa to address the provision of critical resources and technical support to help african countries respond effectively to the pandemic and build resilience for the future; ### 204. notes that the european response has played an important role in supporting r&d efforts in africa and europe to address the provision of critical resources and technical support to help african countries respond effectively to the pandemic and build resilience for the future;


### 205. notes that the covid-19 task force of the commission’s directorate-general for internal market , industry , entrepreneurship and smes (dg grow) was central to increasing the eu’s strategic autonomy and resilience in the face of the pandemic , by supporting research and innovation , strengthening supply chains , and encouraging greater cooperation and coordination between member states; ### 205. notes that the covid-19 task force of the commission’s directorate-general for internal market , industry , entrepreneurship and smes (dg grow) played an important role in increasing the eu’s strategic autonomy and resilience in the face of the pandemic , by supporting research and innovation , strengthening supply chains , and encouraging greater cooperation and coordination between member states;


### 207. considers that although the level of public funding for r&d was sufficient for the rapid development of vaccines , manufacturing capacities in the eu were scaled up too slowly to match needs; ### deleted


### 207. considers that although the level of public funding for r&d was sufficient for the rapid development of vaccines , manufacturing capacities in the eu were scaled up too slowly to match needs; ### 207. considers that even with the considerable level of public funding for r&d for the rapid development of vaccines , manufacturing capacities in the eu were scaled up too slowly to match needs; stresses that sharing ip and know-how is key in order to ensure large-scale production and global availability of medical countermeasures;


### 208. considers it essential to ensure the openness of global supply chains to eu manufacturers , by maintaining close cooperation with the eu’s international partners and counterparts and by responsibly responding to protectionist reflexes from said counterparts , such as the america first principle; ### deleted


### 208. considers it essential to ensure the openness of global supply chains to eu manufacturers , by maintaining close cooperation with the eu’s international partners and counterparts and by responsibly responding to protectionist reflexes from said counterparts , such as the america first principle; ### 208. considers it essential to ensure the openness of global supply chains to eu manufacturers , by maintaining close cooperation with the eu’s international partners and counterparts;


### 209. asks for tools to be set up allowing the commission to implement reciprocal trade policies when needed (to counter the defence production act , for example) , and thereby maintain an equal balance of power and bargaining abilities; ### 209. asks for tools to be set up allowing the commission , after the european parliament and the member states have given their agreement , to implement reciprocal trade policies when needed and thereby maintain an equal balance of power and bargaining abilities;


### 210. emphasises that the eu has taken the lead in the global response and solidarity and must continue to play this role; considers that the eu must continue to lead vaccine solidarity around the world and that vaccine solidarity is part of the eu’s one health approach; ### 210. considers that the eu should continue to lead solidarity in terms of vaccines , medicines and healthcare supplies and equipment around the world and that this kind of solidarity is part of the eu’s one health approach;


### 211. underlines that the world is likely to face new epidemics and pandemics in the future and that the eu’s one health approach entails being active in global preparedness , notably regarding the loss of biodiversity that is driving pandemics; ### deleted


### 211. underlines that the world is likely to face new epidemics and pandemics in the future and that the eu’s one health approach entails being active in global preparedness , notably regarding the loss of biodiversity that is driving pandemics; ### 211. underlines that the world is likely to face new epidemics and pandemics in the future and that the eu’s one health approach entails being active in global preparedness , notably regarding the achievement of the green deal objectives and targets , the respect of the eu environmental law , the promotion of a sustainable development , the urgent and needed cut of co2 emissions , the loss of biodiversity , that are all driving forces at the base of pandemics and zoonotics events;


### 211. underlines that the world is likely to face new epidemics and pandemics in the future and that the eu’s one health approach entails being active in global preparedness , notably regarding the loss of biodiversity that is driving pandemics; ### 211. underlines that prevention is essential to deal with any new epidemics and pandemics in the future and that the one health approach is the healthy solution in global preparedness;


### 212. highlights that in the face of the current geopolitics of globalisation , the eu should detect high-risk dependencies and establish production capacities for related products in the eu; asks for a single market emergency instrument to be established enabling the eu , in the event of a crisis , to act directly and coercively to protect the single market; ### 212. highlights that in the face of the current geopolitics of globalisation , the eu should detect high-risk dependencies and establish production capacities and use all existing development and research capacities in member states , such as the “cantacuzino” national institute for military medical research and development in romania for all products produced in the eu; asks for a single market emergency instrument to be established enabling the eu , in the event of a crisis , to act directly and constructively to protect the single market;


### 213. underlines the need to shift to a more pragmatic trade policy and that targeted protectionist instruments can be appropriate tools to enhance the eu’s bargaining power , protect the eu’s fundamental interests and ultimately ensure that global supply chains are actually open to the eu; ### deleted


### 213. underlines the need to shift to a more pragmatic trade policy and that targeted protectionist instruments can be appropriate tools to enhance the eu’s bargaining power , protect the eu’s fundamental interests and ultimately ensure that global supply chains are actually open to the eu; ### 213. underlines the need to shift to a more pragmatic trade policy and that targeted protectionist instruments based on the ‘made in the eu’ principle can be appropriate tools to enhance the eu’s bargaining power , protect the eu’s fundamental interests and ultimately ensure that global supply chains are actually open to the eu;


### 214. notes the close cooperation between the coalition for epidemic preparedness innovations (cepi) and the global alliance for vaccines and immunizations (gavi) , under the auspices of the who and unicef , leading to the creation of covax , which aimed to ensure that cepi’s funding led to vaccines that would be accessible to all; ### deleted


### 214. notes the close cooperation between the coalition for epidemic preparedness innovations (cepi) and the global alliance for vaccines and immunizations (gavi) , under the auspices of the who and unicef , leading to the creation of covax , which aimed to ensure that cepi’s funding led to vaccines that would be accessible to all; ### 214. welcomes the cooperation between the coalition for epidemic preparedness innovations (cepi) and the global alliance for vaccines and immunizations (gavi) , under the auspices of the who and unicef , leading to the creation of covax , which aimed to ensure that cepi’s funding led to vaccines that would be accessible to all; stresses that these voluntary initiatives needs to be made permanent and well established under the umbrella of the un system , with democratic control and scrutiny associated to it and by ensuring full transparency in their activities;


### 214. notes the close cooperation between the coalition for epidemic preparedness innovations (cepi) and the global alliance for vaccines and immunizations (gavi) , under the auspices of the who and unicef , leading to the creation of covax , which aimed to ensure that cepi’s funding led to vaccines that would be accessible to all; ### 214. (does not affect the english version.)


### 215. notes that cepi used recoverable loans to secure doses on behalf of covax facilities; underlines the fact that while cepi had some contingency funding solutions it had to rely mostly on fundraising; ### 215. notes that cepi used recoverable loans to secure doses on behalf of covax facilities; underlines the fact that while cepi had some contingency funding solutions it had to rely mostly on fundraising; underlines that although this system achieved positive results , public institutions must not rely on voluntary donations to achieve their objective in public health; calls therefore for sufficient competences and resources to be allocated to the appropriate bodies and agencies in the un system and other relevant public authorities in order to fulfil their mandate and protect people's health;


### 215. notes that cepi used recoverable loans to secure doses on behalf of covax facilities; underlines the fact that while cepi had some contingency funding solutions it had to rely mostly on fundraising; ### 215. notes that gavi designed and managed the covax facility , covax’s global risk sharing and pooled procurement mechanism , and secured doses for covax through advance purchase agreements (apas) and the covax dose sharing mechanism , leading global procurement and delivery at scale for covax; notes that cepi used recoverable loans to secure doses on behalf of covax facilities; underlines the fact that while cepi had some contingency funding solutions it had to rely mostly on fundraising;


### 216. welcomes the fact that equitable access to vaccines has been the top priority of global foundations , including cepi and gavi , and that cepi has been putting in practice the not-for-profit / no-loss principle for vaccines intended for low- and middle-income countries; ### 216. notes the fact that equitable access to vaccines has been the top priority of global foundations , including cepi and gavi , and that cepi has not put in practice the not-for-profit / no-loss principle for vaccines intended for low- and middle-income countries , such as eastern european union member states;


### 216. welcomes the fact that equitable access to vaccines has been the top priority of global foundations , including cepi and gavi , and that cepi has been putting in practice the not-for-profit / no-loss principle for vaccines intended for low- and middle-income countries; ### 216. welcomes the fact that equitable access to vaccines has been the top priority of global foundations , including cepi and gavi , and that cepi has been putting in practice the not-for-profit / no-loss principle for vaccines intended for low- and middle-income countries;


### 87. calls for the continuous professional development of healthcare workers and for protective measures for their physical and mental health , as well as vaccinations for them , to be ensured; ### 87. calls on the member states to continuous professional development for healthcare workers is provided in line with existing eu legislation and frameworks; calls on the commission to propose measures to protect healthcare workers physical and mental health , including vaccinations and other protective measures when necessary , to ensure fair and sustainable working conditions; calls on member states to tackle the issue of underpaid healthcare professions and the gender pay gap in healthcare professions , such as nurses and carers , whom are highly-skilled , often low paid and predominantly female;


### 87. calls for the continuous professional development of healthcare workers and for protective measures for their physical and mental health , as well as vaccinations for them , to be ensured; ### 87. calls for the for investments in high quality public healthcare systems and the protection of healthcare workers , their working conditions to be improved and their well being to be fully respected and promoted at all levels; underlines the importance to invest in their continuous professional training and development , also in the field of pandemic surveillance and management; stresses that their safety must always be a priority and recalls the ensure the protection of their physical and mental health , also through the appropriate vaccinations policies;


### 87. calls for the continuous professional development of healthcare workers and for protective measures for their physical and mental health , as well as vaccinations for them , to be ensured; ### 87. calls for the continuous professional development of healthcare workers and for protective measures for their physical and mental health to be ensured;


### 88. looks forwards to the inclusion of mental health in the eu health union; ### 88. calls on the european commission to the include mental health in the eu health union and to acknowledge in their measures that mental and physical health are interlinked and indissociated; calls urgently on the european commission and member states to take measures to tackle the mental health crisis caused by the covid-19 pandemic; reminds in this context that especially young people and children have been affected , which will have long-term consequences on our societies if not addressed quickly;


### 88. looks forwards to the inclusion of mental health in the eu health union; ### 88. looks forwards to the inclusion of mental health and health education in the eu health union;


### 88. looks forwards to the inclusion of mental health in the eu health union; ### 88. underlines that mental health in the eu health union package must be a priority;


### 89. calls on the member states to properly finance their health systems in order to ensure their immediate and long-term resilience , and to invest in critical health infrastructure , tools , structures , processes and laboratory capacity; ### 89. calls on the member states to properly finance their healthcare systems in order to ensure their immediate and long-term resilience , their capacity to protect and promote people's health , their availability to all in the eu; reminds the importance to invest in critical health working forces , infrastructure , tools , structures , processes and laboratory capacity;


### 89. calls on the member states to properly finance their health systems in order to ensure their immediate and long-term resilience , and to invest in critical health infrastructure , tools , structures , processes and laboratory capacity; ### 89. calls on the member states to properly finance their health systems in order to ensure their immediate and long-term resilience , and to invest in critical health infrastructure , tools , structures , processes and laboratory capacity and in educational institutions so that health education can be provided;


### 89. calls on the member states to properly finance their health systems in order to ensure their immediate and long-term resilience , and to invest in critical health infrastructure , tools , structures , processes and laboratory capacity; ### 89. calls on the member states to properly finance their health systems in order to ensure their immediate and long-term resilience , and to invest in critical health infrastructure , clinical trials , tools , structures , processes and laboratory capacity;


### 90. believes , considering that by nature pandemics are very unpredictable and with the benefit of hindsight , that lessons need to be learned on how to be better prepared for negotiations with companies in order to avoid ending up with surplus vaccines and medical countermeasures; ### deleted


### 90. believes , considering that by nature pandemics are very unpredictable and with the benefit of hindsight , that lessons need to be learned on how to be better prepared for negotiations with companies in order to avoid ending up with surplus vaccines and medical countermeasures; ### 90. calls on the european commission to grant full transparency on the procedure which lead to closing contracts to purchase covid-19 vaccines; believes , considering that by nature pandemics are very unpredictable , that lessons need to be learned on how to be better prepared for negotiations in joint procurement procedures for medicines and medical products , how to ensure transparency also in crisis situations and when time is pressing , in order to guarantee democratic oversight , enhance citizens trust in public institutions , including eu institutions , and to warrant for an optimal cost-benefit solution , including avoiding ending up with surplus vaccines and medical countermeasures;


### 90. believes , considering that by nature pandemics are very unpredictable and with the benefit of hindsight , that lessons need to be learned on how to be better prepared for negotiations with companies in order to avoid ending up with surplus vaccines and medical countermeasures; ### 90. believes , considering that by nature pandemics are very unpredictable and with the benefit of hindsight , that lessons need to be learned on how to be better prepared for negotiations with companies;


### 90. believes , considering that by nature pandemics are very unpredictable and with the benefit of hindsight , that lessons need to be learned on how to be better prepared for negotiations with companies in order to avoid ending up with surplus vaccines and medical countermeasures; ### 90. believes , considering that by nature pandemics are very unpredictable and with the benefit of hindsight , that lessons need to be learned and clear rules need to be established on how to be better prepared for negotiations with companies in order to avoid ending up with surplus vaccines and medical countermeasures;


### 91. urges the improvement of common and joint procurement procedures in emergency situations and a more coordinated approach , allowing for contracts to be adapted; ### 91. urges the improvement of common and joint procurement procedures in emergency situations through the adoption of uniform approaches to allow for contracts to be adapted , under the coordination and scrutiny of both the european parliament and national parliaments;


### 92. recommends that the eu establish adequate systems to provide manufacturers with proper at-risk funding during emergencies in order to quickly adapt and scale-up production , avoiding disruptions and shortages of medicines , medical devices and services; ### 92. recommends that the eu foresee the creation of emergency funding in the event of public health crisis to support development and production of the relevant medical countermeasures , to quickly adapt and scale-up production , avoiding disruptions and shortages of health technology , medicines , medical devices and services; such mechanism shall be transparent and contingent to approval and revision of legislation;